Lb Pharmaceuticals (LBRX) Liabilities and Shareholders Equity (2024 - 2026)

Lb Pharmaceuticals' Liabilities and Shareholders Equity history runs 3 years deep, the most recent figure standing at $393.5 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity changed N/A year-over-year to $393.5 million; the TTM figure through Mar 2026 stood at $1.0 billion (changed N/A YoY), while the FY2025 annual figure was $312.9 million, up 833.18% from the prior year.
• Liabilities and Shareholders Equity was $393.5 million for Q1 2026 at Lb Pharmaceuticals, up from $312.9 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $393.5 million in Q1 2026 to a low of $33.5 million in Q4 2024.
• Historically, Liabilities and Shareholders Equity has averaged $265.2 million across 3 years, with a median of $316.8 million in 2025.
• Biggest YoY gain for Liabilities and Shareholders Equity was 833.18% in 2025; the steepest drop was 833.18% in 2025.
• A 3-year view of Liabilities and Shareholders Equity shows it stood at $33.5 million in 2024, then surged by 833.18% to $312.9 million in 2025, then climbed by 25.74% to $393.5 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $393.5 million (Q1 2026), $312.9 million (Q4 2025), and $320.7 million (Q3 2025), per Business Quant data.